Will Charles River Laboratories' (CRL) ADC Partnership Redefine Its Edge in Biotech Collaboration?

• In October 2025, The Francis Crick Institute announced a new collaboration with Charles River Laboratories International to accelerate antibody-drug conjugate (ADC) drug discovery and development by leveraging integrated discovery, profiling, and preclinical technologies.
• This joint initiative aims to fast-track next-generation targeted therapies by combining advanced phage display antibody generation with Charles River's Retrogenix platform for early safety profiling.
• We'll explore how the partnership’s integrated approach to ADC development could influence Charles River’s investment narrative and long-term outlook.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Charles River Laboratories International Investment Narrative Recap

Investors in Charles River Laboratories International often see potential in the company's integrated approach to drug discovery, betting on recovery in biotech funding and successful adoption of advanced therapies. The recent partnership with The Francis Crick Institute to accelerate antibody-drug conjugate (ADC) development could support Charles River’s short-term pipeline visibility, yet is unlikely to materially change the company’s biggest challenge: ongoing backlog conversion issues and recent study cancellations, which continue to pressure near-term revenue growth.

One of the closest ties to this new ADC collaboration is the October 8, 2025, partnership with Toxys. That initiative strengthens Charles River’s position in non-animal testing technologies, supporting evolving regulatory demands and client preferences. Together, these partnerships signal how the company is positioning itself to address sector shifts while balancing its historical reliance on animal-based research.

By contrast, investors should be mindful that continued cancellations and demand softness in long-term studies remain a meaningful concern, especially if...

Read the full narrative on Charles River Laboratories International (it's free!)

Charles River Laboratories International is forecast to reach $4.4 billion in revenue and $483.2 million in earnings by 2028. This outlook relies on 2.8% annual revenue growth and an earnings increase of $552.4 million from the current level of -$69.2 million.

Uncover how Charles River Laboratories International's forecasts yield a $186.87 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Two different fair value estimates for Charles River Laboratories from the Simply Wall St Community span US$186.87 to US$255.41. Many investors remain focused on backlog conversion and organic growth challenges, highlighting why it pays to compare several viewpoints.

Explore 2 other fair value estimates on Charles River Laboratories International - why the stock might be worth just $186.87!

Build Your Own Charles River Laboratories International Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com